A Critical HA1 Neutralizing Domain of H5N1 Influenza in an Optimal Conformation Induces Strong Cross-Protection

PLoS ONE

Volumn 8, Issue 1, 2013, Pages

  Du, Lanying ^a   Zhao, Guangyu ^b   Sun, Shihui ^b   Zhang, Xiujuan ^a   Zhou, Xiaojun ^b   Guo, Yan ^b   Li, Ye ^a,c   Zhou, Yusen ^b   Jiang, Shibo ^a,d  

^a NEW YORK BLOOD CENTER   (United States)

^b BEIJING INSTITUTE OF MICROBIOLOGY AND EPIDEMIOLOGY   (China)

^c WENZHOU MEDICAL UNIVERSITY   (China)

^d FUDAN UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

IMMUNOGLOBULIN G; INFLUENZA VIRUS HEMAGGLUTININ; INFLUENZA VIRUS HEMAGGLUTININ 1; MONOMER; NEUTRALIZING ANTIBODY; RECOMBINANT HEMAGGLUTININ 13 263; RECOMBINANT HEMAGGLUTININ 13 263 FC FUSION PROTEIN; RECOMBINANT HEMAGGLUTININ 13 263 FD FUSION PROTEIN; RECOMBINANT PROTEIN; UNCLASSIFIED DRUG; VACCINE;

AMINO TERMINAL SEQUENCE; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIBODY RESPONSE; ANTIBODY TITER; ARTICLE; CLADISTICS; CONTROLLED STUDY; CROSS PROTECTION; DRUG EFFICACY; DRUG SAFETY; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HISTOPATHOLOGY; INFLUENZA A (H5N1); INFLUENZA VIRUS A H5N1; MOUSE; NONHUMAN; POLYACRYLAMIDE GEL ELECTROPHORESIS; PROTEIN ANALYSIS; PROTEIN CONFORMATION; PROTEIN DOMAIN; PROTEIN STRUCTURE; RECEPTOR BINDING DOMAIN; SURVIVAL RATE; VIRUS NEUTRALIZATION; VIRUS STRAIN; WEIGHT REDUCTION; WESTERN BLOTTING;

ANIMALS; ANTIBODIES, NEUTRALIZING; ANTIBODIES, VIRAL; ANTIGENS, VIRAL; CROSS REACTIONS; FEMALE; HEMAGGLUTININ GLYCOPROTEINS, INFLUENZA VIRUS; HUMANS; INFLUENZA A VIRUS, H5N1 SUBTYPE; INFLUENZA VACCINES; MICE; MICE, INBRED BALB C; NEUTRALIZATION TESTS; PROTEIN CONFORMATION; PROTEIN STRUCTURE, TERTIARY; RECOMBINANT FUSION PROTEINS; VACCINES, SYNTHETIC;

AVES; MAMMALIA;

EID: 84872190107     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0053568     Document Type: Article

References (48)

1. Imai M, Watanabe T, Hatta M, Das SC, Ozawa M, et al. (2012) Experimental adaptation of an influenza H5 HA confers respiratory droplet transmission to a reassortant H5 HA/H1N1 virus in ferrets. Nature 486: 420-428.
2. Herfst S, Schrauwen EJ, Linster M, Chutinimitkul S, de Wit E, et al. (2012) Airborne transmission of influenza A/H5N1 virus between ferrets. Science 336: 1534-1541.
3. Jiang S, Li R, Du L, Liu S, (2010) Roles of the hemagglutinin of influenza A virus in viral entry and development of antiviral therapeutics and vaccines. Protein Cell 1: 342-354.
4. Han T, Sui J, Bennett AS, Liddington RC, Donis RO, et al. (2011) Fine epitope mapping of monoclonal antibodies against hemagglutinin of a highly pathogenic H5N1 influenza virus using yeast surface display. Biochem Biophys Res Commun 409: 253-259.
5. Ekiert DC, Bhabha G, Elsliger MA, Friesen RH, Jongeneelen M, et al. (2009) Antibody recognition of a highly conserved influenza virus epitope. Science 324: 246-251.
6. Garcia JM, Pepin S, Lagarde N, Ma ES, Vogel FR, et al. (2009) Heterosubtype neutralizing responses to influenza A (H5N1) viruses are mediated by antibodies to virus haemagglutinin. PLoS One 4: e7918.
7. Patel A, Tran K, Gray M, Li Y, Ao Z, et al. (2009) Evaluation of conserved and variable influenza antigens for immunization against different isolates of H5N1 viruses. Vaccine 27: 3083-3089.
8. Zhou F, Wang G, Buchy P, Cai Z, Chen H, et al. (2012) A triclade DNA vaccine designed on the basis of a comprehensive serologic study elicits neutralizing antibody responses against all clades and subclades of highly pathogenic avian influenza H5N1 viruses. J Virol 86: 6970-6978.
9. Stevens J, Blixt O, Tumpey TM, Taubenberger JK, Paulson JC, et al. (2006) Structure and receptor specificity of the hemagglutinin from an H5N1 influenza virus. Science 312: 404-410.
10. Khurana S, Suguitan AL Jr, Rivera Y, Simmons CP, Lanzavecchia A, et al. (2009) Antigenic fingerprinting of H5N1 avian influenza using convalescent sera and monoclonal antibodies reveals potential vaccine and diagnostic targets. PLoS Med 6: e1000049.
11. Maines TR, Chen LM, Van HN, Tumpey TM, Blixt O, et al. (2011) Effect of receptor binding domain mutations on receptor binding and transmissibility of avian influenza H5N1 viruses. Virology 413: 139-147.
12. Yen HL, Aldridge JR, Boon AC, Ilyushina NA, Salomon R, et al. (2009) Changes in H5N1 influenza virus hemagglutinin receptor binding domain affect systemic spread. Proc Natl Acad Sci U S A 106: 286-291.
13. Khurana S, Wu J, Verma N, Verma S, Raghunandan R, et al. (2011) H5N1 virus-like particle vaccine elicits cross-reactive neutralizing antibodies that preferentially bind to the oligomeric form of influenza virus hemagglutinin in humans. J Virol 85: 10945-10954.
14. Weldon WC, Wang BZ, Martin MP, Koutsonanos DG, Skountzou I, et al. (2010) Enhanced immunogenicity of stabilized trimeric soluble influenza hemagglutinin. PLoS One 5: e12466.
15. Du L, Leung VH, Zhang X, Zhou J, Chen M, et al. (2011) A recombinant vaccine of H5N1 HA1 fused with foldon and human IgG Fc induced complete cross-clade protection against divergent H5N1 viruses. PLoS One 6: e16555.
16. He Y, Lu H, Siddiqui P, Zhou Y, Jiang S, (2005) Receptor-binding domain of severe acute respiratory syndrome coronavirus spike protein contains multiple conformation-dependent epitopes that induce highly potent neutralizing antibodies. J Immunol 174: 4908-4915.
17. Du L, Zhao G, He Y, Guo Y, Zheng BJ, et al. (2007) Receptor-binding domain of SARS-CoV spike protein induces long-term protective immunity in an animal model. Vaccine 25: 2832-2838.
18. He Y, Zhou Y, Liu S, Kou Z, Li W, et al. (2004) Receptor-binding domain of SARS-CoV spike protein induces highly potent neutralizing antibodies: implication for developing subunit vaccine. Biochem Biophys Res Commun 324: 773-781.
19. Du L, Zhao G, Lin Y, Sui H, Chan C, et al. (2008) Intranasal vaccination of recombinant adeno-associated virus encoding receptor-binding domain of severe acute respiratory syndrome coronavirus (SARS-CoV) spike protein induces strong mucosal immune responses and provides long-term protection against SARS-CoV infection. J Immunol 180: 948-956.
20. Sui J, Hwang WC, Perez S, Wei G, Aird D, et al. (2009) Structural and functional bases for broad-spectrum neutralization of avian and human influenza A viruses. Nat Struct Mol Biol 16: 265-273.
21. Weis WI, Brunger AT, Skehel JJ, Wiley DC, (1990) Refinement of the influenza virus hemagglutinin by simulated annealing. J Mol Biol 212: 737-761.
22. Faden RR, Karron RA, (2012) Public health and biosecurity.The obligation to prevent the next dual-use controversy. Science 335: 802-804.
23. Osterholm MT, Henderson DA, (2012) Public health and biosecurity. Life sciences at a crossroads: respiratory transmissible H5N1. Science 335: 801-802.
24. Berns KI, Casadevall A, Cohen ML, Ehrlich SA, Enquist LW, et al. (2012) Public health and biosecurity. Adaptations of avian flu virus are a cause for concern. Science 335: 660-661.
25. Berns KI, Casadevall A, Cohen ML, Ehrlich SA, Enquist LW, et al. (2012) Policy: Adaptations of avian flu virus are a cause for concern. Nature 482: 153-154.
26. Le Duc JW, Franz DR, (2012) Genetically engineered transmissible influenza A/H5N1: A call for laboratory safety and security. Biosecur Bioterror 10: 153-154.
27. Fouchier R, Osterhaus AB, Steinbruner J, Yuen KY, Henderson DA, et al. (2012) Preventing pandemics: The fight over flu. Nature 481: 257-259.
28. Cox RJ, Pedersen G, Madhun AS, Svindland S, Saevik M, et al. (2011) Evaluation of a virosomal H5N1 vaccine formulated with Matrix M adjuvant in a phase I clinical trial. Vaccine 29: 8049-8059.
29. Langley JM, Risi G, Caldwell M, Gilderman L, Berwald B, et al. (2011) Dose-sparing H5N1 A/Indonesia/05/2005 pre-pandemic influenza vaccine in adults and elderly adults: a phase III, placebo-controlled, randomized study. J Infect Dis 203: 1729-1738.
30. Bodewes R, Kreijtz JH, van AG, Geelhoed-Mieras MM, Verburgh RJ, et al. (2010) A single immunization with CoVaccine HT-adjuvanted H5N1 influenza virus vaccine induces protective cellular and humoral immune responses in ferrets. J Virol 84: 7943-7952.
31. Santiago FW, Fitzgerald T, Treanor JJ, Topham DJ, (2011) Vaccination with drifted variants of avian H5 hemagglutinin protein elicits a broadened antibody response that is protective against challenge with homologous or drifted live H5 influenza virus. Vaccine 29: 8888-8897.
32. Chen MW, Cheng TJ, Huang Y, Jan JT, Ma SH, et al. (2008) A consensus-hemagglutinin-based DNA vaccine that protects mice against divergent H5N1 influenza viruses. Proc Natl Acad Sci U S A 105: 13538-13543.
33. Hessel A, Schwendinger M, Holzer GW, Orlinger KK, Coulibaly S, et al. (2011) Vectors based on modified vaccinia Ankara expressing influenza H5N1 hemagglutinin induce substantial cross-clade protective immunity. PLoS One 6: e16247.
34. Tambyah PA, Wilder-Smith A, Pavlova BG, Barrett PN, Oh HM, et al. (2012) Safety and immunogenicity of two different doses of a Vero cell-derived, whole virus clade 2 H5N1 (A/Indonesia/05/2005) influenza vaccine. Vaccine 30: 329-335.
35. Lin SC, Huang MH, Tsou PC, Huang LM, Chong P, et al. (2011) Recombinant trimeric HA protein immunogenicity of H5N1 avian influenza viruses and their combined use with inactivated or adenovirus vaccines. PLoS One 6: e20052.
36. Tseng CT, Sbrana E, Iwata-Yoshikawa N, Newman PC, Garron T, et al. (2012) Immunization with SARS coronavirus vaccines leads to pulmonary immunopathology on challenge with the SARS virus. PLoS One 7: e35421.
37. Loureiro S, Ren J, Phapugrangkul P, Colaco CA, Bailey CR, et al. (2011) Adjuvant-free immunization with hemagglutinin-Fc fusion proteins as an approach to influenza vaccines. J Virol 85: 3010-3014.
38. Meier S, Guthe S, Kiefhaber T, Grzesiek S, (2004) Foldon, the natural trimerization domain of T4 fibritin, dissociates into a monomeric A-state form containing a stable beta-hairpin: atomic details of trimer dissociation and local beta-hairpin stability from residual dipolar couplings. J Mol Biol 344: 1051-1069.
39. Chen X, Lu L, Qi Z, Lu H, Wang J, et al. (2010) Novel recombinant engineered gp41 N-terminal heptad repeat trimers and their potential as anti-HIV-1 therapeutics or microbicides. J Biol Chem 285: 25506-25515.
40. Wei CJ, Xu L, Kong WP, Shi W, Canis K, et al. (2008) Comparative efficacy of neutralizing antibodies elicited by recombinant hemagglutinin proteins from avian H5N1 influenza virus. J Virol 82: 6200-6208.
41. Zhang MY, Wang Y, Mankowski MK, Ptak RG, Dimitrov DS, (2009) Cross-reactive HIV-1-neutralizing activity of serum IgG from a rabbit immunized with gp41 fused to IgG1 Fc: possible role of the prolonged half-life of the immunogen. Vaccine 27: 857-863.
42. Pleass RJ, (2009) Fc-receptors and immunity to malaria: from models to vaccines. Parasite Immunol 31: 529-538.
43. Martyn JC, Cardin AJ, Wines BD, Cendron A, Li S, et al. (2009) Surface display of IgG Fc on baculovirus vectors enhances binding to antigen-presenting cells and cell lines expressing Fc receptors. Arch Virol 154: 1129-1138.
44. Khurana S, Larkin C, Verma S, Joshi MB, Fontana J, et al. (2011) Recombinant HA1 produced in E. coli forms functional oligomers and generates strain-specific SRID potency antibodies for pandemic influenza vaccines. Vaccine 29: 5657-5665.
45. Qi Z, Pan C, Lu H, Shui Y, Li L, et al. (2010) A recombinant mimetics of the HIV-1 gp41 prehairpin fusion intermediate fused with human IgG Fc fragment elicits neutralizing antibody response in the vaccinated mice. Biochem Biophys Res Commun 398: 506-512.
46. Du L, Zhao G, Zhang X, Liu Z, Yu H, et al. (2010) Development of a safe and convenient neutralization assay for rapid screening of influenza HA-specific neutralizing monoclonal antibodies. Biochem Biophys Res Commun 397: 580-585.
47. Chou TC, (2006) Theoretical basis, experimental design, and computerized simulation of synergism and antagonism in drug combination studies. Pharmacol Rev 58: 621-681.
48. Zhao G, Du L, Xiao W, Sun S, Lin Y, et al. (2010) Induction of protection against divergent H5N1 influenza viruses using a recombinant fusion protein linking influenza M2e to Onchocerca volvulus activation associated protein-1 (ASP-1) adjuvant. Vaccine 28: 7233-7240.